Recent developments include MaxCyte's Q2 2026 earnings call and financial results reporting a net loss but revenue exceeding expectations, and a multi-platform technology license partnership with Genentech announced in July 2026.

• MaxCyte reported Q2 2026 financial results with revenue of $7.27 million and a net loss of $8.87 million; EPS was -$0.08 per share [N2][S2].
• The company held $15.0 million in cash and $90.6 million in short-term investments as of June 30, 2026, with a strong liquidity position reflected in a current ratio of 12.26 [S2].
• MaxCyte held a Q2 2026 earnings call highlighting operational and financial results [N1].
• In July 2026, MaxCyte signed a multi-platform technology license partnership with Genentech, expanding its commercial collaborations [N7].

MaxCyte's technology platform addresses the growing demand for non-viral delivery methods in next-generation cell and gene therapies, which are increasingly complex and require scalable, efficient, and safe intracellular delivery solutions. The company's ExPERT platform's ability to deliver diverse molecules into a wide range of cell types with high viability and at commercial scale positions it well within a rapidly expanding market. The SPL agreements provide a diversified and potentially significant source of milestone and sales-based revenue, enhancing long-term revenue visibility. Strategic partnerships, such as the multi-platform technology license agreement with Genentech, demonstrate industry validation and potential for expanded commercial opportunities. The acquisition of SeQure Dx broadens the company's service offerings, supporting customers earlier in their development processes.

MaxCyte operates in a highly competitive and rapidly evolving cell therapy market where technological advances and customer preferences can shift. The company reported net losses in recent quarters, reflecting ongoing investment in R&D and commercialization efforts, which may pressure financial performance. The reliance on SPL agreements for milestone and sales-based payments introduces variability and dependency on customers' clinical and commercial success. Market adoption of non-viral delivery methods, while growing, may face challenges from alternative technologies or regulatory hurdles. Additionally, the company's financial position, while currently strong in liquidity, requires continued operational execution to achieve sustainable profitability.

MaxCyte's competitive strengths include its proprietary and patented Flow Electroporation technology platform, which offers high efficiency, viability, and consistency in delivering a broad range of molecules into almost any cell type at scale. The ExPERT platform's flexibility to scale from research to cGMP manufacturing on a single platform without re-optimization is a significant advantage. The company benefits from a robust intellectual property portfolio with over 200 granted patents and more than 100 pending applications worldwide. Its FDA Master File, continuously updated since 2002, supports regulatory submissions for customers and has been referenced in over 75 clinical trials, reducing clinical risk and development timelines. The SPL agreement business model provides recurring revenue and potential milestone payments, aligning MaxCyte's success with that of its customers. The company's deep domain expertise, experienced management team, and customer-focused scientific support further strengthen its market position.

• Dependence on Customer Clinical and Commercial Success: MaxCyte's revenue from SPL agreements depends on the successful advancement and commercialization of its customers' cell therapy programs, which are subject to clinical, regulatory, and market risks.
• Competitive and Technological Risks: The cell therapy and gene editing markets are rapidly evolving with competing technologies; MaxCyte must continue to innovate and maintain its technology leadership to sustain its market position.
• Financial Performance and Profitability: The company has reported net losses reflecting investments in R&D and commercialization; sustained losses could impact liquidity and operational flexibility.
• Regulatory and Manufacturing Risks: Changes in regulatory requirements or challenges in scaling manufacturing processes could affect the adoption and use of MaxCyte's platform by customers.

• MaxCyte, Inc. is a commercial cell engineering company focused on enabling platform technologies for next-generation cell therapeutics including cell and gene therapies and cell-based R&D [S1].
• The company has developed and commercialized proprietary Flow Electroporation® technology used by biopharmaceutical companies for complex cell engineering [S1].
• Electroporation is a method to introduce molecules into cells by applying an electric field to increase cell membrane permeability temporarily [S1].
• MaxCyte's ExPERT platform, based on Flow Electroporation technology, includes five instruments (DTx, ATx, STx, GTx, VLx) and related disposables and consumables, designed to support scalable cell engineering from research to commercial manufacturing [S1].
• The ExPERT platform delivers high efficiency, viability, and consistency in transfection, supporting delivery of diverse molecules into almost any cell type, including hard-to-transfect human primary cells [S1].
• The platform supports scale-up from tens of thousands to tens of billions of cells in a single transfection run within 30 minutes, suitable for cGMP manufacturing environments [S1].
• MaxCyte's technology is used by leading biopharmaceutical companies, including a majority of the top 25 pharmaceutical companies by 2024 revenue, and academic/government institutions such as the NIH [S1].
• The company has 32 Strategic Partner License (SPL) customers, with SPL agreements providing recurring revenue and potential milestone and sales-based payments, with a total pre-commercial milestone opportunity exceeding $2 billion across 31 SPL agreements [S1].
• MaxCyte acquired SeQure Dx in January 2025, expanding its assay and service offerings for cell and gene therapy developers [S1].
• The company maintains an FDA Master File supporting regulatory submissions for its customers, referenced in over 75 clinical trials [S1].
• As of June 30, 2026, MaxCyte had cash and cash equivalents of $15.0 million and short-term investments of $90.6 million, totaling $121.3 million in current assets against $9.9 million in current liabilities, resulting in a current ratio of 12.26 and a cash ratio of 10.68 [S2].
• For the quarter ended June 30, 2026, MaxCyte reported revenue of $7.27 million and a net loss of $8.87 million, with basic and diluted EPS of -$0.08 [S2].
• Recent news includes a multi-platform technology license partnership with Genentech announced in July 2026 and Q2 2026 earnings call highlights and results reported in August 2026 [N1][N2][N7].
• The company reported a Q2 2026 loss but revenue exceeded prior expectations as per recent news [N2].